Moran Mieron
Chief Tech/Sci/R&D Officer chez UROGEN PHARMA LTD.
Profil
Moran Mieron is currently working as the Director of Research & Development at Pluristem Ltd.
and as the Director of Research & Pre-Clinical Affairs at UroGen Pharma Ltd.
Previously, he worked as the Vice President of Research & Development at Cellect Biotechnology Ltd.
from 2014 to 2016.
Dr. Mieron holds a graduate and doctorate degree from Technion-Israel Institute of Technology.
Postes actifs de Moran Mieron
| Sociétés | Poste | Début |
|---|---|---|
| UROGEN PHARMA LTD. | Chief Tech/Sci/R&D Officer | - |
Pluristem Ltd.
 Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Moran Mieron
| Sociétés | Poste | Fin |
|---|---|---|
| QUOIN PHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | 15/05/2016 |
Formation de Moran Mieron
| Technion-Israel Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| UROGEN PHARMA LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
Cellect Biotechnology Ltd.
 Cellect Biotechnology Ltd. Medical SpecialtiesHealth Technology Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel. | Health Technology |
